Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment

ABSTRACT: PURPOSE OF REVIEW: Treatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous disease biology, and a rapidly evolving treatment landscape. Here, we highlight the importance of determining fitness, review the late...

Descripción completa

Detalles Bibliográficos
Autores principales: de Leeuw, David C., Ossenkoppele, Gert J., Janssen, Jeroen J. W. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Geriatric Oncology (L Balducci, Section Editor)
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606099/
https://www.ncbi.nlm.nih.gov/pubmed/35653050
http://dx.doi.org/10.1007/s11912-022-01299-9
_version_ 1784818225354113024
author de Leeuw, David C.
Ossenkoppele, Gert J.
Janssen, Jeroen J. W. M.
author_facet de Leeuw, David C.
Ossenkoppele, Gert J.
Janssen, Jeroen J. W. M.
author_sort de Leeuw, David C.
collection PubMed
description ABSTRACT: PURPOSE OF REVIEW: Treatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous disease biology, and a rapidly evolving treatment landscape. Here, we highlight the importance of determining fitness, review the latest therapeutic developments, and discuss clinical scenarios to provide guidance on individualized treatment for older AML patients. RECENT FINDINGS: Several factors, like age, performance status, and comorbidities, play a role in fitness and are associated with outcome. Comorbidity scoring systems and geriatric assessments are tools to help physicians select the most appropriate treatment for each patient. The addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and enhanced formulas of existing drugs like CPX-351 and oral azacitidine have improved responses and outcomes. SUMMARY: New drugs and combination therapies have increased the therapeutic options for elderly AML patients but determination of fitness and disease biology is essential to select patient-tailored treatments.
format Online
Article
Text
id pubmed-9606099
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-96060992022-10-28 Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment de Leeuw, David C. Ossenkoppele, Gert J. Janssen, Jeroen J. W. M. Curr Oncol Rep Geriatric Oncology (L Balducci, Section Editor) ABSTRACT: PURPOSE OF REVIEW: Treatment of elderly patients with acute myeloid leukemia is a known challenge for hematologists due to patient diversity, heterogeneous disease biology, and a rapidly evolving treatment landscape. Here, we highlight the importance of determining fitness, review the latest therapeutic developments, and discuss clinical scenarios to provide guidance on individualized treatment for older AML patients. RECENT FINDINGS: Several factors, like age, performance status, and comorbidities, play a role in fitness and are associated with outcome. Comorbidity scoring systems and geriatric assessments are tools to help physicians select the most appropriate treatment for each patient. The addition of venetoclax, targeted therapy with IDH1/2 and FLT3 inhibitors, and enhanced formulas of existing drugs like CPX-351 and oral azacitidine have improved responses and outcomes. SUMMARY: New drugs and combination therapies have increased the therapeutic options for elderly AML patients but determination of fitness and disease biology is essential to select patient-tailored treatments. Springer US 2022-06-02 2022 /pmc/articles/PMC9606099/ /pubmed/35653050 http://dx.doi.org/10.1007/s11912-022-01299-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Geriatric Oncology (L Balducci, Section Editor)
de Leeuw, David C.
Ossenkoppele, Gert J.
Janssen, Jeroen J. W. M.
Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
title Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
title_full Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
title_fullStr Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
title_full_unstemmed Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
title_short Older Patients with Acute Myeloid Leukemia Deserve Individualized Treatment
title_sort older patients with acute myeloid leukemia deserve individualized treatment
topic Geriatric Oncology (L Balducci, Section Editor)
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9606099/
https://www.ncbi.nlm.nih.gov/pubmed/35653050
http://dx.doi.org/10.1007/s11912-022-01299-9
work_keys_str_mv AT deleeuwdavidc olderpatientswithacutemyeloidleukemiadeserveindividualizedtreatment
AT ossenkoppelegertj olderpatientswithacutemyeloidleukemiadeserveindividualizedtreatment
AT janssenjeroenjwm olderpatientswithacutemyeloidleukemiadeserveindividualizedtreatment

Ejemplares similares